NO961204L - Triaryletylenderivater for anvendelse innen terapi - Google Patents

Triaryletylenderivater for anvendelse innen terapi

Info

Publication number
NO961204L
NO961204L NO961204A NO961204A NO961204L NO 961204 L NO961204 L NO 961204L NO 961204 A NO961204 A NO 961204A NO 961204 A NO961204 A NO 961204A NO 961204 L NO961204 L NO 961204L
Authority
NO
Norway
Prior art keywords
therapy
derivatives
agents
triarylethylene
triarylethylene derivatives
Prior art date
Application number
NO961204A
Other languages
English (en)
Other versions
NO306292B1 (no
NO961204D0 (no
Inventor
Donald Paul Matthews
Alan Joseph Bitonti
William Anthony Van Sickle
Donald Alan Kaplan
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/259,797 external-priority patent/US5525633A/en
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO961204L publication Critical patent/NO961204L/no
Publication of NO961204D0 publication Critical patent/NO961204D0/no
Publication of NO306292B1 publication Critical patent/NO306292B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO961204A 1993-09-24 1996-03-25 Triaryletylenderivater for anvendelse innen terapi NO306292B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12661493A 1993-09-24 1993-09-24
US08/259,797 US5525633A (en) 1993-09-24 1994-06-15 Triaryl-ethylene derivatives
PCT/US1994/009314 WO1995008528A1 (en) 1993-09-24 1994-08-19 Triaryl-ethylene derivatives for use in therapy

Publications (3)

Publication Number Publication Date
NO961204L true NO961204L (no) 1996-03-25
NO961204D0 NO961204D0 (no) 1996-03-25
NO306292B1 NO306292B1 (no) 1999-10-18

Family

ID=26824862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961204A NO306292B1 (no) 1993-09-24 1996-03-25 Triaryletylenderivater for anvendelse innen terapi

Country Status (17)

Country Link
US (1) US5684004A (no)
EP (1) EP0720597B1 (no)
JP (1) JPH09503761A (no)
CN (1) CN1131415A (no)
AT (1) ATE165594T1 (no)
AU (1) AU678535B2 (no)
CA (1) CA2171728C (no)
DE (1) DE69409961T2 (no)
DK (1) DK0720597T3 (no)
ES (1) ES2115975T3 (no)
FI (1) FI961339L (no)
HU (1) HUT75933A (no)
IL (1) IL111018A0 (no)
NO (1) NO306292B1 (no)
NZ (1) NZ273433A (no)
PL (1) PL177833B1 (no)
WO (1) WO1995008528A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI961339A0 (fi) 1996-03-22
HU9600727D0 (en) 1996-05-28
EP0720597B1 (en) 1998-04-29
ES2115975T3 (es) 1998-07-01
NO306292B1 (no) 1999-10-18
DE69409961D1 (de) 1998-06-04
PL313594A1 (en) 1996-07-08
FI961339A7 (fi) 1996-03-22
CN1131415A (zh) 1996-09-18
CA2171728C (en) 2001-11-13
NO961204D0 (no) 1996-03-25
ATE165594T1 (de) 1998-05-15
US5684004A (en) 1997-11-04
DE69409961T2 (de) 1998-09-10
EP0720597A1 (en) 1996-07-10
PL177833B1 (pl) 2000-01-31
NZ273433A (en) 1997-11-24
WO1995008528A1 (en) 1995-03-30
AU7670794A (en) 1995-04-10
AU678535B2 (en) 1997-05-29
HUT75933A (en) 1997-05-28
DK0720597T3 (da) 1998-10-07
CA2171728A1 (en) 1995-03-30
IL111018A0 (en) 1994-11-28
FI961339L (fi) 1996-03-22
JPH09503761A (ja) 1997-04-15

Similar Documents

Publication Publication Date Title
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
PT935465E (pt) Compostos novos de imidazole substituido
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
DK1036058T3 (da) Adamantanderivater
DE69808130D1 (de) Adamantan-derivate
ID23374A (id) Halogenopirimidin
ATE247470T1 (de) Neue substituierte imidazolverbindungen
DK0711140T3 (da) Antimykotisk opløsning til negle
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
FI953497A7 (fi) Spirosykloalkyylisubstituoidut atsetidinonit, jotka ovat käyttökelpoisia hypokolesteroleemisina aineina
ATE167670T1 (de) N-alkylthiopolyaminderivate als radioprotektive mittel
MX9201681A (es) 4,5-dihidro-1h-pirazol-1-carboxiamidas 3,4,n-sustituidas y su uso como inseticidas.
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
RU95101375A (ru) Производные n-(3-аминопропил)-n-фенил-5,6,7,8-тетрагидронафталин-2-карбоксамида, их получение и применение в терапии
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
FI970448A7 (fi) N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat k äyttökelpoisia neuroleptisina aineina
NO961204D0 (no) Triaryletylenderivater for anvendelse innen terapi
BG100248A (bg) Инхибитори на скваленсинтетаза
BG101221A (bg) N-заместени азабициклохептанови производни, приложими като невролептици
ES2152315T3 (es) Xamoneline tartrato.
TR200103126T2 (tr) Yapısal titremenin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri
BR9611904A (pt) Dioxidos de ditiazol
ES1020705Y (es) Maquina portatil perfeccionada multiuso.
ES1024223Y (es) Unidad hermetica de uso personal.
BG102613A (en) New substituted imidazoles